Title

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
A Prospective, Open-label, Phase I/III Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency
  • Phase

    Phase 2/Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    fibrinogen (human) ...
  • Study Participants

    36
The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in patients with congenital fibrinogen deficiency.
The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.
Study Started
Mar 31
2013
Primary Completion
May 18
2020
Study Completion
Nov 18
2020
Last Update
Jul 27
2022
Estimate

Biological BT524 (fibrinogen concentrate from human plasma)

single intravenous infusion

BT524 Experimental

Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)

Criteria

Inclusion Criteria:

Known congenital afibrinogenemia or severe congenital hypofibrinogenemia
Plasma fibrinogen activity ≤ 0.5 g/l and antigen ≤ 0.5 g/l
Male or female
Age 0 to 75 years, with the first ten patients will be 18 years or
Presumed to be compliant with the study procedures and to terminate the study as scheduled
Willing and able to be hospitalized for 3 days for the pharmacokinetic assessment (if applicable)
Willing and able to be hospitalized - if required - in case of interventions (e.g., surgical procedures, major bleeds)
Written informed consent by the patient, his/her parents or by the patient's legal / authorized representative as applicable

Exclusion Criteria:

Known congenital dysfibrinogenemia
Known bleeding disorder other than congenital fibrinogen deficiency
History of esophageal variceal bleeding
Known presence or history of venous/arterial thrombosis or thromboembolic event in the preceding 6 months
Known presence or history of fibrinogen inhibitory antibodies
Known presence or history of hypersensitivity to human fibrinogen or human plasma proteins e.g., immunoglobulins, vaccines or hypersensitivity to any of the excipients
Known positive serology for HIV-1 and HIV-2
Clinically relevant biochemical or hematological findings (except due to underlying disease or emergency bleeding) outside the normal range (at the investigator's discretion)
Clinically relevant pathological findings in physical examination including electrocardiogram (ECG)
Treatment with any fibrinogen concentrate and/or fibrinogen-containing product within 2 weeks prior to infusion of BT524
Concomitant medication interacting relevantly with the coagulation system (e.g., low molecular weight heparin, unfractioned heparin, factor Xa inhibitors, factor IIa inhibitors or PY12 inhibitors) within 2 weeks prior to infusion of BT524
Recent vaccination (within 3 weeks prior to infusion)
Body weight (BW) below 22 kg for patients ≥ 6 years; BW below the 5th percentile of the normal range for children < 6 years (refers to local standard)
End stage disease
Abuse of drugs
Unable to understand and follow the study requirements
Participation in another interventional clinical study within 30 days before entering the study or during the study
Pregnant/ nursing woman, or woman of childbearing potential not using reliable/ effective contraceptive method(s) during the study and at least one month after the last administration of study drug (e.g., oral/ injectable/ implantable/ insertable/ topical hormonal contraceptives, intrauterine devices, female sterilization, partner's vasectomy or condoms)
Any other condition that, to the investigator's judgment, could have an impact on patient's safety or the study results
Elective surgery during the 14 day PK blood sampling period
Acute infection
Clinically relevant increase or decrease in body temperature
Actively bleeding or anticipated bleeding (including female menorrhea) at the time point of or within 7 days prior to infusion of BT524
Surgery within 7 days prior to infusion of BT524
Immobilization within 7 days prior to infusion of BT524
Intake of alcohol or significantly increased intake of caffeine containing products within 24 hours prior to infusion of BT524
Blood donation or comparable blood loss within 60 days prior to infusion of BT524
Excessive physical exercise (extreme sports activities, sauna) within 72 hours prior to infusion of BT524
No Results Posted